Endothelial Targets in Stroke: Translating Animal Models to Human.

Cerebral ischemia (stroke) induces injury to the cerebral endothelium that may contribute to parenchymal injury and worsen outcome. This review focuses on current preclinical studies examining how to prevent ischemia-induced endothelial dysfunction. It particularly focuses on targets at the endothelium itself. Those include endothelial tight junctions, transcytosis, endothelial cell death, and adhesion molecule expression. It also examines how such studies are being translated to the clinic, especially as adjunct therapies for preventing intracerebral hemorrhage during reperfusion of the ischemic brain. Identification of endothelial targets may prove valuable in a search for combination therapies that would specifically protect different cell types in ischemia.

[1]  D. Tancredi,et al.  Exacerbated brain edema in a rat streptozotocin model of hyperglycemic ischemic stroke: Evidence for involvement of blood–brain barrier Na–K–Cl cotransport and Na/H exchange , 2019, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[2]  S. Doré,et al.  Neuroinflammatory mechanisms of blood-brain barrier damage in ischemic stroke. , 2019, American journal of physiology. Cell physiology.

[3]  T. Magnus,et al.  The cerebral endothelial cell as a key regulator of inflammatory processes in sterile inflammation , 2019, Journal of Neuroimmunology.

[4]  Zhiping Hu,et al.  A review of the role of cav-1 in neuropathology and neural recovery after ischemic stroke , 2018, Journal of Neuroinflammation.

[5]  R. Keep,et al.  Claudin-1-Dependent Destabilization of the Blood–Brain Barrier in Chronic Stroke , 2018, The Journal of Neuroscience.

[6]  J. Badaut,et al.  Involvement of caveolin-1 in neurovascular unit remodeling after stroke: Effects on neovascularization and astrogliosis , 2018, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[7]  W. Fang,et al.  Immune Cells After Ischemic Stroke Onset: Roles, Migration, and Target Intervention , 2018, Journal of Molecular Neuroscience.

[8]  Yao Yao Basement membrane and stroke , 2018, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[9]  J. Simard,et al.  Profile of intravenous glyburide for the prevention of cerebral edema following large hemispheric infarction: evidence to date , 2018, Drug design, development and therapy.

[10]  J. Griffin,et al.  Activated protein C, protease activated receptor 1, and neuroprotection. , 2018, Blood.

[11]  Michael M. Wang,et al.  Expression of periaxin (PRX) specifically in the human cerebrovascular system: PDZ domain-mediated strengthening of endothelial barrier function , 2018, Scientific Reports.

[12]  Lee Kissel,et al.  Immune responses in stroke: how the immune system contributes to damage and healing after stroke and how this knowledge could be translated to better cures? , 2018, Immunology.

[13]  J. Ryu,et al.  Fibrinogen in neurological diseases: mechanisms, imaging and therapeutics , 2018, Nature Reviews Neuroscience.

[14]  Guiling Xiang,et al.  Effects of edaravone, the free radical scavenger, on outcomes in acute cerebral infarction patients treated with ultra-early thrombolysis of recombinant tissue plasminogen activator , 2018, Clinical Neurology and Neurosurgery.

[15]  Zhiqiang Ma,et al.  Focusing on claudin-5: A promising candidate in the regulation of BBB to treat ischemic stroke , 2017, Progress in Neurobiology.

[16]  M. Bennett,et al.  Blood-brain barrier dysfunction and recovery after ischemic stroke , 2017, Progress in Neurobiology.

[17]  M. Papa,et al.  Neuro-Coagulopathy: Blood Coagulation Factors in Central Nervous System Diseases , 2017, International journal of molecular sciences.

[18]  C. Iadecola The Neurovascular Unit Coming of Age: A Journey through Neurovascular Coupling in Health and Disease , 2017, Neuron.

[19]  J. Griffin,et al.  Can adjunctive therapies augment the efficacy of endovascular thrombolysis? A potential role for activated protein C , 2017, Neuropharmacology.

[20]  Mohammad Hossein Khosravi,et al.  Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2017, Lancet.

[21]  R. Medcalf,et al.  Selective inhibition of brain endothelial Rho-kinase-2 provides optimal protection of an in vitro blood-brain barrier from tissue-type plasminogen activator and plasmin , 2017, PloS one.

[22]  Takenori Yamaguchi,et al.  Edaravone with and without .6 Mg/Kg Alteplase within 4.5 Hours after Ischemic Stroke: A Prospective Cohort Study (PROTECT4.5). , 2017, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[23]  Hülya Bayır,et al.  The far-reaching scope of neuroinflammation after traumatic brain injury , 2017, Nature Reviews Neurology.

[24]  M. Elkind,et al.  Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, placebo-controlled, double-blind phase 2 trial , 2017, The Lancet Neurology.

[25]  D. Lawrence,et al.  Randomized assessment of imatinib in patients with acute ischaemic stroke treated with intravenous thrombolysis , 2017, Journal of internal medicine.

[26]  Jun Chen,et al.  Cerebral Vascular Disease and Neurovascular Injury in Ischemic Stroke , 2017, Circulation research.

[27]  M. Bennett,et al.  Endothelium-targeted overexpression of heat shock protein 27 ameliorates blood–brain barrier disruption after ischemic brain injury , 2017, Proceedings of the National Academy of Sciences.

[28]  N. Oku,et al.  Combination therapy with liposomal neuroprotectants and tissue plasminogen activator for treatment of ischemic stroke , 2017, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[29]  C. Sommer Ischemic stroke: experimental models and reality , 2017, Acta Neuropathologica.

[30]  B. Molyneaux,et al.  Safety and efficacy of intravenous glyburide on brain swelling after large hemispheric infarction (GAMES-RP): a randomised, double-blind, placebo-controlled phase 2 trial , 2016, The Lancet Neurology.

[31]  P. Sandercock,et al.  Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis , 2016, The Lancet Neurology.

[32]  Xiaoling Chen,et al.  The fate of medications evaluated for ischemic stroke pharmacotherapy over the period 1995–2015 , 2016, Acta pharmaceutica Sinica. B.

[33]  R. Coimbra,et al.  Injury, inflammation and the emergence of human‐specific genes , 2016, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[34]  P. Nahirney,et al.  Ultrastructural analysis of blood–brain barrier breakdown in the peri-infarct zone in young adult and aged mice , 2016, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[35]  C. Lawrence,et al.  The blood–brain barrier after stroke: Structural studies and the role of transcytotic vesicles , 2016, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[36]  R. Keep,et al.  Rapid endothelial cytoskeletal reorganization enables early blood–brain barrier disruption and long-term ischaemic reperfusion brain injury , 2016, Nature Communications.

[37]  R. Keep,et al.  Junctional proteins of the blood-brain barrier: New insights into function and dysfunction , 2016, Tissue barriers.

[38]  Zhen Zhao,et al.  Establishment and Dysfunction of the Blood-Brain Barrier , 2015, Cell.

[39]  A. Buchan,et al.  The transient intraluminal filament middle cerebral artery occlusion model as a model of endovascular thrombectomy in stroke , 2015, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[40]  Sara G. Murray,et al.  Blood coagulation protein fibrinogen promotes autoimmunity and demyelination via chemokine release and antigen presentation , 2015, Nature Communications.

[41]  F. Shi,et al.  Combination of the Immune Modulator Fingolimod With Alteplase in Acute Ischemic Stroke: A Pilot Trial , 2015, Circulation.

[42]  X. Ji,et al.  Normobaric Hyperoxia Slows Blood–Brain Barrier Damage and Expands the Therapeutic Time Window for Tissue-Type Plasminogen Activator Treatment in Cerebral Ischemia , 2015, Stroke.

[43]  D. Ma,et al.  Protective Effects of Non-Anticoagulant Activated Protein C Variant (D36A/L38D/A39V) in a Murine Model of Ischaemic Stroke , 2015, PloS one.

[44]  I. Bechmann,et al.  Blood—Brain Barrier Breakdown Involves Four Distinct Stages of Vascular Damage in Various Models of Experimental Focal Cerebral Ischemia , 2015, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[45]  R. Keep,et al.  Inhibition of junctional adhesion molecule-A/LFA interaction attenuates leukocyte trafficking and inflammation in brain ischemia/reperfusion injury , 2014, Neurobiology of Disease.

[46]  P. Bath,et al.  Inhibition of Rho‐kinase protects cerebral barrier from ischaemia‐evoked injury through modulations of endothelial cell oxidative stress and tight junctions , 2014, Journal of neurochemistry.

[47]  A. Nimmerjahn,et al.  Stepwise Recruitment of Transcellular and Paracellular Pathways Underlies Blood-Brain Barrier Breakdown in Stroke , 2014, Neuron.

[48]  J. Griffin,et al.  Activated Protein C Analog Protects From Ischemic Stroke and Extends the Therapeutic Window of Tissue-Type Plasminogen Activator in Aged Female Mice and Hypertensive Rats , 2013, Stroke.

[49]  Á. Corbí,et al.  N2 Neutrophils, Novel Players in Brain Inflammation After Stroke: Modulation by the PPAR&ggr; Agonist Rosiglitazone , 2013, Stroke.

[50]  K. Furie,et al.  Selective ROCK2 inhibition in focal cerebral ischemia , 2013, Annals of clinical and translational neurology.

[51]  Yongbo Zhang,et al.  Rho kinase: A new target for treatment of cerebral ischemia/reperfusion injury , 2013, Neural regeneration research.

[52]  H. Hara,et al.  A Rho kinase (ROCK) inhibitor, fasudil, prevents matrix metalloproteinase-9-related hemorrhagic transformation in mice treated with tissue plasminogen activator , 2012, Neuroscience.

[53]  R. Keep,et al.  Relocalization of Junctional Adhesion Molecule A during Inflammatory Stimulation of Brain Endothelial Cells , 2012, Molecular and Cellular Biology.

[54]  D. Stern,et al.  Cilostazol Reduces the Risk of Hemorrhagic Infarction After Administration of Tissue-Type Plasminogen Activator in a Murine Stroke Model , 2012, Stroke.

[55]  R. Takahashi,et al.  Cilostazol, a phosphodiesterase inhibitor, prevents no-reflow and hemorrhage in mice with focal cerebral ischemia , 2012, Experimental Neurology.

[56]  Z. Wang,et al.  Systematic assessment and meta-analysis of the efficacy and safety of fasudil in the treatment of cerebral vasospasm in patients with subarachnoid hemorrhage , 2011, European Journal of Clinical Pharmacology.

[57]  K. Arai,et al.  Cellular Mechanisms of Neurovascular Damage and Repair After Stroke , 2011, Journal of child neurology.

[58]  T. Iwama,et al.  Phosphodiesterase-III Inhibitor Prevents Hemorrhagic Transformation Induced by Focal Cerebral Ischemia in Mice Treated with tPA , 2010, PloS one.

[59]  G. D. del Zoppo Acute anti‐inflammatory approaches to ischemic stroke , 2010, Annals of the New York Academy of Sciences.

[60]  C. Sommer,et al.  Oxygen Therapy Reduces Secondary Hemorrhage after Thrombolysis in Thromboembolic Cerebral Ischemia , 2010, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[61]  Susan C Fagan,et al.  Minocycline and Tissue-Type Plasminogen Activator for Stroke: Assessment of Interaction Potential , 2009, Stroke.

[62]  D. Stewart,et al.  Expression of endothelial phosphorylated caveolin‐1 is increased in brain injury , 2009, Neuropathology and applied neurobiology.

[63]  Ken Arai,et al.  Combination therapy with normobaric oxygen (NBO) plus thrombolysis in experimental ischemic stroke , 2009, BMC Neuroscience.

[64]  K. Liu,et al.  Normobaric Hyperoxia Reduces the Neurovascular Complications Associated With Delayed Tissue Plasminogen Activator Treatment in a Rat Model of Focal Cerebral Ischemia , 2009, Stroke.

[65]  S. D. de Morais,et al.  Comparative gene expression profiles of ABC transporters in brain microvessel endothelial cells and brain in five species including human. , 2009, Pharmacological research.

[66]  Marc Fisher,et al.  Update of the Stroke Therapy Academic Industry Roundtable Preclinical Recommendations , 2009, Stroke.

[67]  Toru Yamashita,et al.  Dissociation and Protection of the Neurovascular Unit after Thrombolysis and Reperfusion in Ischemic Rat Brain , 2009, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[68]  S. Nagahiro,et al.  Edaravone, a Free Radical Scavenger, Inhibits MMP-9–Related Brain Hemorrhage in Rats Treated With Tissue Plasminogen Activator , 2009, Stroke.

[69]  K. Rhodes,et al.  Extension of the Thrombolytic Time Window With Minocycline in Experimental Stroke , 2008, Stroke.

[70]  Myron D. Ginsberg,et al.  Neuroprotection for ischemic stroke: Past, present and future , 2008, Neuropharmacology.

[71]  Ulf Eriksson,et al.  Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke , 2008, Nature Medicine.

[72]  J. Simard,et al.  Brain oedema in focal ischaemia: molecular pathophysiology and theoretical implications , 2007, The Lancet Neurology.

[73]  R. Keep,et al.  Protein Kinase Cα-RhoA Cross-talk in CCL2-induced Alterations in Brain Endothelial Permeability* , 2006, Journal of Biological Chemistry.

[74]  Takeshi Hayashi,et al.  Extension of ischemic therapeutic time window by a free radical scavenger, Edaravone, reperfused with tPA in rat brain , 2004, Neurological research.

[75]  John H. Zhang,et al.  Molecular Determinants of the Prothrombogenic and Inflammatory Phenotype Assumed by the Postischemic Cerebral Microcirculation , 2003, Stroke.

[76]  R. Keep,et al.  Blood—Brain Barrier Permeability and Brain Concentration of Sodium, Potassium, and Chloride during Focal Ischemia , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[77]  K. Takakura,et al.  Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Results of a prospective placebo-controlled double-blind trial. , 1992, Journal of neurosurgery.

[78]  H. C. Moises,et al.  Blood to Brain Sodium Transport and Interstitial Fluid Potassium Concentration during Early Focal Ischemia in the Rat , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[79]  U. Degirolami,et al.  Tissue plasminogen activator reduces neurological damage after cerebral embolism. , 1985, Science.

[80]  J. Garcìa,et al.  Temporary regional cerebral ischemia in the cat. A model of hemorrhagic and subcortical infarction. , 1977, Journal of neuropathology and experimental neurology.

[81]  A. Ommaya,et al.  Temporary Occlusion of the Middle Cerebral Artery in the Monkey: Clinical and Pathological Observations , 1970, Stroke.

[82]  R. Shenkar,et al.  RhoA Kinase Inhibition With Fasudil Versus Simvastatin in Murine Models of Cerebral Cavernous Malformations , 2017, Stroke.

[83]  M. O’Donnell Blood-brain barrier Na transporters in ischemic stroke. , 2014, Advances in pharmacology.